INmune Bio Newsroom

BTIG Maintains INmune Bio(INMB.US) With Buy Rating, Maintains Target Price $21

Moomoo NewsNov 1 08:36 ET

Scotiabank Maintains INmune Bio(INMB.US) With Buy Rating, Maintains Target Price $22

Moomoo NewsNov 1 08:35 ET

A. G. P. Initiates INmune Bio(INMB.US) With Buy Rating, Announces Target Price $20

Moomoo NewsOct 21 07:31 ET

INmune Bio Analyst Ratings

BenzingaOct 21 07:25 ET

INmune Bio Initiated With a Buy at Alliance Global Partners

TipRanksOct 21 07:10 ET

Scotiabank Maintains INmune Bio(INMB.US) With Buy Rating, Maintains Target Price $22

Moomoo NewsOct 1 09:31 ET

Inmune Bio (INMB) Receives a Buy From Scotiabank

TipRanksOct 1 09:29 ET

INmune Bio Analyst Ratings

BenzingaSep 27 13:12 ET

Maxim Group Maintains INmune Bio(INMB.US) With Buy Rating, Maintains Target Price $22

Moomoo NewsSep 27 12:32 ET

BTIG Maintains INmune Bio(INMB.US) With Buy Rating, Maintains Target Price $21

Moomoo NewsSep 27 06:31 ET

Buy Rating Affirmed for Inmune Bio on Promising Clinical Data and Market Potential

TipRanksSep 27 06:18 ET

Raymond James Initiates INmune Bio(INMB.US) With Buy Rating, Announces Target Price $18

Moomoo NewsSep 26 17:31 ET

INmune Bio Initiated With an Outperform at Raymond James

TipRanksSep 26 16:32 ET

Maxim Group Maintains INmune Bio(INMB.US) With Buy Rating, Maintains Target Price $22

Moomoo NewsSep 18 15:31 ET

Scotiabank Maintains INmune Bio(INMB.US) With Buy Rating, Maintains Target Price $22

Moomoo NewsSep 18 08:31 ET

Analysts Offer Insights on Healthcare Companies: Inmune Bio (INMB) and Zevra Therapeutics (ZVRA)

TipRanksSep 18 07:44 ET

BTIG Maintains INmune Bio(INMB.US) With Buy Rating, Maintains Target Price $21

Moomoo NewsSep 18 07:34 ET

Inmune Bio's Promising AD Treatment Approach Merits Buy Rating, Analyst Says

TipRanksSep 18 06:51 ET

INmune Bio Analyst Ratings

BenzingaAug 22 08:34 ET

Scotiabank Initiates Coverage On INmune Bio With Sector Outperform Rating, Announces Price Target of $22

BenzingaAug 22 08:34 ET